134 related articles for article (PubMed ID: 7030942)
21. IgM antibodies against phenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship to bacterial index and erythema nodosum leprosum.
Schwerer B; Meeker HC; Sersen G; Levis WR
Acta Leprol; 1984; 2(2-4):394-402. PubMed ID: 6398598
[TBL] [Abstract][Full Text] [Related]
22. Induction of lepromin positivity by a candidate anti-leprosy vaccine Mycobacterium w in lepromin negative healthy contacts of multibacillary leprosy patients.
Kar HK; Sharma AK; Misra RS; Zaheer SA; Mukherjee A; Mukherjee R; Beena KR; Kaur H; Nair SK; Talwar GP
Indian J Lepr; 1992; 64(4):495-500. PubMed ID: 1308525
[TBL] [Abstract][Full Text] [Related]
23. A vaccine from ICRC bacilli against M. leprae infection in mouse foot-pad.
Bhide MB; Pradhan KS; Bapat CV
Lepr India; 1978 Jul; 50(3):334-44. PubMed ID: 359922
[No Abstract] [Full Text] [Related]
24. Under-explored experimental topics related to integral mycobacterial vaccines for leprosy.
Gormus BJ; Meyers WM
Expert Rev Vaccines; 2003 Dec; 2(6):791-804. PubMed ID: 14711362
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
[TBL] [Abstract][Full Text] [Related]
26. Comparison of various preparations of Mycobacterium leprae and other mycobacteria by lymphocyte stimulation.
Bjune G
Int J Lepr Other Mycobact Dis; 1978; 46(3-4):386-93. PubMed ID: 83309
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
[TBL] [Abstract][Full Text] [Related]
28. [Lepromin scars in leprosy patients and persons without manifestations of the disease tested with human antigen and various concentrations of armadillo antigens (double-blind study)].
Bechelli LM; Haddad N; Guimaraes Pagnano PM; Garrido Neves R; Melchior E; Carminatti Fregnan R
Acta Leprol; 1979; (76-77):173-9. PubMed ID: 121832
[No Abstract] [Full Text] [Related]
29. Immunogenic "subunit" of the ICRC antileprosy vaccine.
Chirmule NB; Chaturvedi RM; Deo MG
Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):27-35. PubMed ID: 3131465
[TBL] [Abstract][Full Text] [Related]
30. Extended studies on subclinical infection in leprosy.
Bharadwaj VP; Ramu G; Desikan KV; Katoch K
Indian J Lepr; 1984; 56(4):807-12. PubMed ID: 6398341
[No Abstract] [Full Text] [Related]
31. Immunology and animal experimentation in leprosy.
Shepard CC
Cutis; 1976 Jul; 18(1):80-96. PubMed ID: 797549
[No Abstract] [Full Text] [Related]
32. Research in leprosy. A report of a committee set up by the medical research council to study future prospects.
Clin Exp Immunol; 1979 Apr; 36(1):1-7. PubMed ID: 380853
[TBL] [Abstract][Full Text] [Related]
33. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients.
Andreoli A; Brett SJ; Draper P; Payne SN; Rook GA
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):211-7. PubMed ID: 3894538
[TBL] [Abstract][Full Text] [Related]
34. Fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with Mycobacterium leprae.
Abe M; Minagawa F; Yoshino Y; Ozawa T; Saikawa K; Saito T
Int J Lepr Other Mycobact Dis; 1980 Jun; 48(2):109-19. PubMed ID: 6156918
[No Abstract] [Full Text] [Related]
35. A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
Garraud O; Ribierre O; Bach MA
Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):38-45. PubMed ID: 2940306
[TBL] [Abstract][Full Text] [Related]
36. Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients.
Shinde SR; Chiplunkar SV; Butlin R; Samson PD; Deo MG; Gangal SG
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):51-8. PubMed ID: 8326181
[TBL] [Abstract][Full Text] [Related]
37. Two candidate antileprosy vaccines--current status of their development.
Talwar GP; Fotedar A
Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):550-2. PubMed ID: 6368418
[No Abstract] [Full Text] [Related]
38. Adoptive transfer of tolerance induced by ICRC bacilli against Mycobacterium leprae in mice.
Jeevan A; Bapat CV; Deo MG
Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):437-45. PubMed ID: 3528346
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis.
Seckl MJ
Int J Lepr Other Mycobact Dis; 1985 Dec; 53(4):618-40. PubMed ID: 3910750
[No Abstract] [Full Text] [Related]
40. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
